Breaking News

Pfizer Makes Final Bid for AstraZeneca

May 19, 2014

Ups offer to $120 billion

Pfizer has made its fourth and final proposal to acquire AstraZeneca in a transaction valued at $120 billion, with 45% in cash. This latest offer represents a 45% increase of the total price and values AstraZeneca shares at £55 ($92.48) each. AstraZeneca declined to comment, but is reviewing the statement Pfizer issued.
 
Pfizer set forth terms of an improved proposal with a value of £53.50, with Pfizer and AstraZeneca shareholders owning approximately 74% and 26%, respectively, of the combined company. The initial proposal dating back to January valued the company at $98.7 billion.
 
Pfizer confirmed that it will not make a hostile offer directly to AstraZeneca shareholders and will only proceed with an offer with the recommendation of the board of directors of AstraZeneca
 
Both companies have aging portfolios and losses due to generic competition. Sales for each company fell 6% in 2013 with Pfizer's sales at $51.6 billion and AstraZeneca's at $25.7 billion.
blog comments powered by Disqus
  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision

  • The Impact of Sample Handling  and Processing on the Outcome of Bioanalytical Testing

    The Impact of Sample Handling and Processing on the Outcome of Bioanalytical Testing

    Haiko Pillu, Head Technical Operations, Life Science Services, SGS Belgium NV||September 8, 2016
    Optimizing bioanalytical procedures to get reliable results in clinical studies

  • Quality Risk Management

    Quality Risk Management

    Cheryl Abernathy and Bryan Sasbon, Quality Assurance Operations Manager, Ropack Pharma Solutions; QA Director & Regulatory Affairs, Ropack Pharma Solutions||September 8, 2016
    Embracing the process as a means to a strong quality culture